Trastuzumab Deruxtecan

(asked on 26th April 2024) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what representations she has made to NICE on the availability of Enhertu.


Answered by
Andrew Stephenson Portrait
Andrew Stephenson
This question was answered on 2nd May 2024

The Department meets regularly with the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including access to medicines. The NICE has recommended Enhertu, also known as trastuzumab deruxtecan and made by Daiichi Sankyo, for use through the Cancer Drugs Fund, for the treatment of HER2-positive metastatic or unresectable breast cancer. It is available to eligible National Health Service patients in England, in line with the NICE’s recommendations.

The NICE is currently evaluating Enhertu for the treatment of HER2-low metastatic or unresectable breast cancer. Following negotiations between NHS England and the company, which concluded without a commercial agreement to make it available at a cost-effective price for the NHS, the NICE published final draft guidance on 5 March 2024, that does not recommend it as an option for this indication. The NICE remains open to further discussions with NHS England and the company, and currently expects to publish final guidance on 15 May 2024.

Reticulating Splines